Ansai S, Goto K, Aoki T, Hozumi Y, Aso K
Department of Dermatology, Yamagata University, Faculty of Medicine, Japan.
Clin Exp Dermatol. 1993 Sep;18(5):470-5. doi: 10.1111/j.1365-2230.1993.tb02255.x.
A case of malignant haemangioendothelioma of the scalp in an 82-year-old female treated with intralesional, intra-arterial and intravenous recombinant interleukin-2 (rIL-2) is reported. The scalp lesions disappeared after injection of 35,350,000 Japan reference units of rIL-2 and excision of the residual tumour. Immunohistochemical characterization of the cells infiltrating the lesion after rIL-2 administration revealed 30-40% CD4+ and CD8+ T lymphocytes, 20-30% macrophages and 5-10% natural killer cells. These findings are similar to those in other human cancers. Almost all of the cells in the intersticies of the lesion after rIL-2 injection expressed leucocyte function-associated antigen-1, and some of the tumour cells and the infiltrating cells around them expressed intercellular adhesion molecule-1. HLA-DR-positive cells markedly increased in number after rIL-2 administration. This report suggests that rIL-2 administration is the most effective therapy for malignant haemangioendothelioma.
报告了1例82岁女性头皮恶性血管内皮瘤患者，采用瘤内、动脉内和静脉内注射重组白细胞介素-2（rIL-2）进行治疗。在注射3535万日本参考单位的rIL-2并切除残余肿瘤后，头皮病变消失。rIL-2给药后浸润病变的细胞的免疫组织化学特征显示，有30%-40%的CD4+和CD8+ T淋巴细胞、20%-30%的巨噬细胞以及5%-10%的自然杀伤细胞。这些发现与其他人类癌症中的发现相似。rIL-2注射后病变间隙中的几乎所有细胞均表达白细胞功能相关抗原-1，部分肿瘤细胞及其周围的浸润细胞表达细胞间黏附分子-1。rIL-2给药后HLA-DR阳性细胞数量明显增加。本报告提示，rIL-2给药是治疗恶性血管内皮瘤最有效的疗法。
